American Diabetes Association’s 71st Scientific Sessions

June 24–28, 2011 – San Diego Convention Center

June 2, 2011 -- 

The Immune Tolerance Network is conducting a portfolio of innovative intervention research trials in new-onset type 1 diabetes.

Join us for the following preliminary trial result presentations:

Tuesday, June 28th

AbATE Study (hOKT3γ1(Ala-Ala); teplizumab), by Kevan Herold, MD and Stephen Gitelman, MD.

Monday, June 27th

Rapamycin plus IL-2 combination therapy in subjects with T1D results in a sustained increase in IL-2 responsiveness and a transient decrease in C-peptide levels, by Carla Greenbaum, MD

Visit Us at 71st Scientific Sessions Booth #2648 and
Learn More About Our Type 1 Diabetes Clinical Trials

 

 

More Information


Directions to the San Diego Convention center.

More details regarding the 71st Scientific Sessions (2011).


Learn about ITN type 1 diabetes trials currently underway:

RETAIN LogoResearch Trial of Aralast NP in New-onset Type 1 Diabetes: www.retainstudy.org
T1DAL LogoInducing Remission in New-onset Type 1 Diabetes with Alefacept: www.t1dal.org